<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20181215041975N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2019-01-02</date_registration>
      <primary_sponsor>Shiraz University of Medical Sciences</primary_sponsor>
      <public_title>Investigation of the effect of electrical stimulation of the brain on the basis of EEG in stuttering</public_title>
      <acronym></acronym>
      <scientific_title>Electroencephalogram-Informed transcranial electrical stimulation together with speech therapy to remediate stuttering</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2019-01-21</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>30</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/36067</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Other design features: In this study, the use of stimulation based on electrophysiologic data analysis of individuals (personalized treatment) is going to compare to a common predetermined protocol in previous studies, Randomization description: Subjects were selected by random sampling from the community of stuttering adults. After meeting the inclusion and exclusion criteria of the study, they were assigned ,with a random number table, in one of two groups of study and control by simple random allocation method, Blinding description: The assessment of stuttering in the preceding, subsequent and follow-up intervention stages will be carried out by speech therapists who are blind to the assignment
Participants will be blinded to the assignment
Speech therapist is blind to the allocation so that after the assembly of the device and the installation of a non-transparent special hat by the operator, she enters the treatment room
The brain signal recorders are blind to the allocation
The brain signal analyzers are blind to the allocation
The main researcher will be stayed blind up yo the end of the follow-up phase to the allocation. When the results of the stuttering assessment and brain signal analysis by the relevant agents at the end of the implementation of the plan were provided, the allocation information from the operator of the device, which is independent of the plan for analysis, will be received for statistical analyses.</study_design>
      <phase>N/A</phase>
      <hc_freetext>STUTTERING.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: Features in the electroencephalogram(EEG) signals related to fluent and non-fluent statements that determine the frequency and areas of electric stimulation will be determined in each subject. َThe montage and type of electrical stimulation will be selected based on the significant differences between the two modes of fluent and non-fluent statements in terms of power or phase coherence. Frequency bands and phase coherence affecting the speech fluency will be administered on areas marked with the 10 -20 system by direct (tDCS) or alternative (tACS) electrical stimulation. This stimulation together with speech therapy will be provided in two weeks, 5 days a week and 30 minutes a day. Intervention 2: Control group:  Features in the EEG signals related to fluent and non-fluent statements that determine the frequency and areas of electric stimulation will be determined in each subject.The montage and type of electrical stimulation, based on the common protocol in stuttering, will be anodal tDCS stimulation over FC5(10-20 system) and reference electrode on supra orbital ridge. This stimulation together with speech therapy will be provided in two weeks, 5 days a week and 30 minutes a day.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
The total individual participants' data is unobtrusive after being unidentified
The report is a collaborative clinical study

When:
Access to individual data 6 months after publishing the results for one year
Access to the clinical report after publishing the results for one year

To whom:
Researchers at universities

Conditions:
Commitment to mention the source name and principal researcher for any use
Commitment to non-application for clinical purposes

Where to obtain:
Corresponding with the agent of project executor, Masoumeh Bayat, with the postal address: masumeh_bayat@yahoo.com

How to obtain:
Investigate the application by the agent of project executor (1 month), and sharing the application with the project executor (1 month), and final statement by the agent of project executor

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Masoumeh Batat</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Unit 8, Number 22, Seifoori Alley, Mojahedin-e Eslam Ave, Shohada Sq</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1156836449</zip>
        <telephone>+98 21 3350 2375</telephone>
        <email>masumeh_bayat@yahoo.com</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Mohammad Nami</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>The School of Advanced Medical Sciences and Technologies, Almas Building, Alley 29, Qasrodasht Ave</address>
        <city>Shiraz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>7133654361</zip>
        <telephone>+98 71 3230 5471</telephone>
        <email>torabinami@sums.ac.ir</email>
        <affiliation>Shiraz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Affected by developmental stuttering with moderate to very severe
Persian speaking
Right-handed
Without sensory, linguistic, and cognitive problems
Holding a diploma, at least
male</inclusion_criteria>
      <agemin>18 years</agemin>
      <agemax>54 years</agemax>
      <gender>Male</gender>
      <exclusion_criteria>History of speech, language, cognitive, or hearing disorder( except for stuttering) according to self report
Acquired and developmental neurological disorders
Having a history of speech therapy from 3 months ago</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>F98.5</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Speech that is characterized by frequent repetition or prolongation of sounds or syllables or words, or by frequent hesitations or pauses that disrupt the rhythmic flow of speech. It should be classified as a disorder only if its severity is such as to ma</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Devices</i_code>
      <i_code>Treatment - Devices</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: Features in the electroencephalogram(EEG) signals related to fluent and non-fluent statements that determine the frequency and areas of electric stimulation will be determined in each subject. َThe montage and type of electrical stimulation will be selected based on the significant differences between the two modes of fluent and non-fluent statements in terms of power or phase coherence. Frequency bands and phase coherence affecting the speech fluency will be administered on areas marked with the 10 -20 system by direct (tDCS) or alternative (tACS) electrical stimulation. This stimulation together with speech therapy will be provided in two weeks, 5 days a week and 30 minutes a day.</i_keyword>
      <i_keyword>Control group:  Features in the EEG signals related to fluent and non-fluent statements that determine the frequency and areas of electric stimulation will be determined in each subject.The montage and type of electrical stimulation, based on the common protocol in stuttering, will be anodal tDCS stimulation over FC5(10-20 system) and reference electrode on supra orbital ridge. This stimulation together with speech therapy will be provided in two weeks, 5 days a week and 30 minutes a day.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Stuttering severity based on ssi-4  and oases. Timepoint: Measuring the stuttering severity at the beginning of the study, immediately after the intervention and three months after the intervention. Method of measurement: Stuttering severity instrument-4 edition and Overall assessment the speaker`s experience of stuttering--adults.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Shiraz University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-10-27</approval_date>
        <contact_name>Ethics committee of Shiraz University of Medical Sciences</contact_name>
        <contact_address>Vice-Chancellor for Research, Shiraz University of Medical Sciences, Zand Blvd., Shiraz, Iran shiraz Fars Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
